文献速递免疫规划传染病防控与疫情报告

日本儿童PCV13接种对成人肺炎链球菌肺炎血清型分布及临床特征的影响

Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
PubMed 文献 · Vaccine · 2019-04-08

本研究为日本多中心前瞻性研究(J-PAVE),比较儿童PCV13纳入免疫规划前后两个阶段(2011–2014年与2016–2017年)成人社区获得性肺炎中肺炎链球菌血清型分布及临床特征。共纳入484例≥15岁患者,PCV13血清型占比从53%降至33%(p<0.001),PPV23非PCV13血清型无变化(p=0.754)。PCV13血清型与血尿素氮升高(调整OR 2.49;95%CI 1.49–4.16)及住院(调整OR 1.74;95%CI 1.02–2.95)风险增加相关。

要点

  • 儿童PCV13接种后成人PCV13血清型肺炎占比从53%降至33%。
  • PCV13血清型与血尿素氮升高及住院风险增加相关。
  • PPV23非PCV13血清型占比未变,且未见上述关联。

核心结论

  • 儿童PCV13纳入免疫规划后,成人肺炎链球菌肺炎中疫苗覆盖血清型所致病例大幅减少。
  • PCV13血清型与肺炎严重程度(血尿素氮升高及住院)相关。

研究设计与样本

  • 多中心前瞻性研究,第一期为2011–2014年,第二期为2016–2017年,在日本社区医院开展。
  • 共纳入484例≥15岁社区获得性肺炎患者,第一期241例,第二期243例。

主要发现

  • PCV13血清型占比从53%降至33%(p<0.001)。
  • PPV23非PCV13血清型占比无变化(p=0.754)。
  • PCV13血清型与血尿素氮升高相关(调整OR 2.49;95%CI 1.49–4.16)。
  • PCV13血清型与住院相关(调整OR 1.74;95%CI 1.02–2.95)。
  • 上述关联在PPV23非PCV13血清型患者中未观察到。

临床怎么用

  • 提示儿童PCV13接种可间接减少成人疫苗血清型肺炎球菌肺炎负担。
  • 成人肺炎链球菌肺炎中,PCV13血清型感染可能提示更高住院风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The pediatric 13-valent pneumococcal conjugate vaccine (PCV13) was included in the pediatric immunization programme in Japan in late 2013. The impact of vaccination on the serotype distribution and clinical characteristics of pneumococcal pneumonia has not been described. METHODS: The first phase of this multicentre prospective study was conducted at community-based hospitals in Japan from 2011 to 2014. The second phase was conducted from 2016 to 2017. Pneumococcal isolates and clinical data were collected from patients with community-acquired pneumonia who were ≥15 years of age. Patients were classified by pneumococcal serotype to PCV13 serotype, 23-valent pneumococcal polysaccharide vaccine (PPV23) non-PCV13 serotype, and non-vaccine serotype. RESULTS: A total of 484 patients were enrolled, 241 in the first phase and 243 in the second. The proportion of PCV13 serotypes decreased from 53% to 33% (p < 0.001), whereas PPV23 non-PCV13 serotypes did not change (p = 0.754). PCV13 serotypes were associated with increased risk of elevated blood urea nitrogen (adjusted odds ratio 2.49; 95% confidence interval: 1.49-4.16) and hospitalization (adjusted odds ratio 1.74; 95% confidence interval: 1.02-2.95). These associations were not observed in patients with PPV23 non-PCV13 serotypes. CONCLUSIONS: The occurrence of pneumococcal pneumonia caused by vaccine-covered serotypes dramatically decreased following the introduction of pediatric PCV13. The PCV13 serotypes were associated with pneumonia severity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sando E, Suzuki M, Furumoto A, et al. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE). Vaccine. 2019. PMID: 30975569. doi:10.1016/j.vaccine.2019.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。